imagingbavituximab antiviralclinical trialsoverviewunderstanding clinical trialsbavituximab trialspublicationspublicationsposters and presentationsbiomanufacturinginvestorsupcoming eventsnews releasessec filingscorporate governancestock quote & chartanalyst coverageinvestor faqse mail alerts peregrine pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics to stimulate the body s immune system to fight cancer . contact us avid sitemap 01 02 pause frontpage slideshow copyright 2006 2014 joomlaworks ltd. recent publication ps targeting antibodies augment anti pd 1 in preclinical models of triple negative breast cancer . read publication archived event october 13 2016 peregrine pharmaceuticals annual shareholder meeting . webcast replay in the news monday october 10 2016 peregrine pharmaceuticals reports top line and initial biomarker data from phase iii sunrise trial of bavituximab in oral presentation at european society for medical oncology esmo 2016 congress tuesday september 27 2016 peregrine pharmaceuticals presents preclinical data demonstrating ps targeting antibodies significantly enhance the anti tumor activity of multiple checkpoint targeting agents in model of triple negative breast cancer tnbc wednesday september 21 2016 peregrine pharmaceuticals provides update on oral presentation of top line data from phase iii sunrise trial of bavituximab at european society for medical oncology esmo 2016 congress more news copyright 2003 2016 peregrine pharmaceuticals inc. all rights reserved disclaimersafe harbor